EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study

Elizabeth T Loggers iD, Rashmi Chugh, Noah Federman, Lee Hartner, Richard F Riedel iD, Sunny Cho, David Hyslop, Allison Lim, Ana B Oton, Kutluk H Oktay iD

Cancer · 15.08.2024 · 130 (16) · 2812-2821

DOI: 10.1002/cncr.35324 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Cancer, online erschienen am 04.05.2024. Verfasst von Elizabeth T Loggers und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Division, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, University of Washington, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Desmoid Tumors, Ovary, Tetrahydronaphthalenes. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Springworks Therapeutics, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Nirogacestat is a targeted gamma secretase inhibitor approved in the United States for adults with progressing desmoid tumors. In the phase 3 DeFi study (NCT03785964) of nirogacestat, ovarian toxicity (OT) was identified as a safety signal among females of reproductive potential (FORP). This analysis further describes the incidence, presentation, and resolution of OT.

Methods

Patients were randomized to twice‐daily oral nirogacestat (150 mg) or placebo, taken in continuous 28‐day cycles. Investigator‐identified OT in FORP was based on abnormal reproductive hormone values or perimenopausal symptoms (or both). Adverse event follow‐up was conducted to assess OT resolution. Post hoc analyses included return of menstruation and return of follicle‐stimulating hormone (FSH) to within normal limits (WNL) (≤20.4 mIU/mL).

Results

Of 92 randomized females, 73 in the safety population were FORP ( n = 36 nirogacestat, n = 37 placebo). OT was identified in 75% (27 of 36) receiving nirogacestat and 0% (0 of 37) receiving placebo. As of October 24, 2022, investigators reported OT resolution in 78% (21 of 27) of patients, with median OT duration of 19.1 weeks. Off‐treatment resolution was reported in all 11 patients (100%) who stopped nirogacestat treatment; of these, all nine with available menstruation information experienced return of menstruation and eight had FSH WNL at last reported assessment. Resolution was reported in 10 of 14 (71%) while on nirogacestat; of these, all 10 experienced return of menstruation and seven had FSH WNL. Two patients were lost to follow‐up.

Conclusion

Most FORP treated with nirogacestat experienced OT, with the majority resolving, including all who stopped treatment, suggesting that OT is transient.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Desmoid TumorsOvaryTetrahydronaphthalenesAdolescentAdultAgedFemaleHumansMiddle AgedYoung AdultDouble-Blind MethodFollicle Stimulating HormoneValine

Stichwörter der Autor:innen

GSIfertilitygamma secretaseoncologyovarian dysfunctionwomen of childbearing potential

Substanzen

Follicle Stimulating HormoneTetrahydronaphthalenesnirogacestatValine

Autor:innen und Institutionen

  • Clinical Research Division, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, University of Washington, Seattle, Washington, USA.
  • University of Michigan, Rogel Comprehensive Cancer Center, Ann Arbor, Michigan, USA.
  • Departments of Pediatrics and Orthopaedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
  • University of Pennsylvania, Abramson Cancer Center, Pennsylvania Hospital, Philadelphia, Pennsylvania, USA.
  • Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA.
  • SpringWorks Therapeutics, Inc, Stamford, Connecticut, USA.

ORCID-Profile: Elizabeth T Loggers, Richard F Riedel, Kutluk H Oktay

Förderung

  • Springworks Therapeutics, Inc

Zitieren

APA

Loggers, E. T., Chugh, R., Federman, N., Hartner, L., Riedel, R. F., Cho, S., Hyslop, D., Lim, A., Oton, A. B., & Oktay, K. H. (2024). Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study. Cancer, 130(16), 2812-2821. https://doi.org/10.1002/cncr.35324

Vancouver

Loggers ET, Chugh R, Federman N, Hartner L, Riedel RF, Cho S, et al. Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study. Cancer. 2024;130(16):2812-2821. doi:10.1002/cncr.35324

BibTeX
@article{Loggers2024,
  author = {Loggers, Elizabeth T and Chugh, Rashmi and Federman, Noah and Hartner, Lee and Riedel, Richard F and Cho, Sunny and Hyslop, David and Lim, Allison and Oton, Ana B and Oktay, Kutluk H},
  title = {Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study},
  journal = {Cancer},
  year = {2024},
  volume = {130},
  number = {16},
  pages = {2812--2821},
  doi = {10.1002/cncr.35324}
}
Kostenlos starten →